ProShares Trust - ProShares UltraShort Yen -2x Shares
YCS
Get informed when a big investor buys or sells
+ FollowMarket Cap$37.19B
Close$
$90.05
55.7% upside
Current Fair Value
55.7% upsideUndervalued by 55.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $37.19 Billion |
|---|---|
| Enterprise Value | $37.01 Billion |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | -0.4 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2834.16 |
| Enterprise Value to EBIT | -492.37 |
| Enterprise Value to Net Income | -525 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.0559▲ 154.87% |
|---|---|
| Total Calls | 16,100▲ 133.33% |
| Total Puts | 65,300▲ 277.46% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 17.67%▼ 3.42% |
|---|---|
| Total Invested | $5.59M▼ 12.79% |
| Investors Holding | 9▼ 2.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...